Romosozumab signif increases bone mineral density and bone content compared with teriparatide (EurekAlert, 11 June 2014)

11 Jun 2014


In a new study presented at the European League Against Rheumatism Annual Congress, scientists have shown that romosozumab caused an increase in bone mineral density and bone content in postmenopausal women with low bone mass.

Full article


Related Topics

Bone

Share this story